XTLB (XTL Biopharmaceuticals) Short Interest


XTLB XTL Biopharmaceuticals Ltd XTLB
24 GF Score
Price $2.57
! 2 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XTLB vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, XTL Biopharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XTL Biopharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Short Interest falls into.


XTLB
24GF Score
XTL Biopharmaceuticals Ltd XTLB
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
24GF Score

Get the complete analysis for XTLB

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.57
Price